Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

European Society for Medical Oncology (ESMO) Asia

December 06 - 08, 2024

Durvalumab
Durvalumab + Tremelimumab
Trastuzumab Deruxtecan

ppt

Safety of 30 min infusion of durvalumab in combination with gemcitabine-based chemotherapy in first-line treatment of advanced biliary tract cancer: TOURMALINE early results

pdf

Impact of baseline tumour burden on outcomes in EMERALD-1: A phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolisation in embolisation-eligible unresectable hepatocellular carcinoma

pdf

PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT),

ppt

Five-year overall survival and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

ppt

Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis

pdf

Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis [Plain languagae summary]

pdf

Randomized, open-label, multicenter, Phase 3 study of trastuzumab deruxtecan and rilvegostomig vs standard of care in first-line, HER2-expressing, locally advanced or metastatic biliary tract cancer: DESTINY-BTC01

pdf

An open-label, multicenter, phase 2 study of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: DESTINY PanTumor02 part 2

pdf

A Phase 1b/2 open-label study evaluating trastuzumab deruxtecan in combination with rilvegostomig and chemotherapy in patients with HER2+ and HER2-low gastric cancers: DESTINY-Gastric03 Part 4

pdf

Real-world treatment patterns in patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinomain East Asia

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização